Fundraising Fox

Volitionrx

NYSE: VNRX

Henderson, US · Delaware corporation

volition.com ↗

Volition develops Nu.Q epigenetics-based blood tests that detect nucleosome changes associated with cancer, sepsis, and other diseases in both humans and animals. Its products include diagnostic assays for NETosis detection, research-use assays, and a canine cancer blood test.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

JM
Jacob MicallefChief Scientific Officer
JMJake Micallef
Jake MicallefChief Scientific Officer
ME
Mark EcclestonCo-founding Scientist
TH
Terig HughesGroup Chief Financial Officer
ST
Salvatore Thomas ButeraExecutive
RR
Rodney RootsaertExecutive
LB
Louise BatchelorGroup Chief Marketing & Communications Officer
GF
Gael ForterreChief Licensing Officer
GMGaetan Michel
Gaetan MichelChief Operating Officer
JKJasmine Kway
Jasmine KwayChief Revenue Officer
DC
David Cecil VanstonChief Financial Officer
JT
Jason TerrellChief Medical Officer

Reported raises · per SEC filings

Form D private placements

$52.6M disclosed across 8 rounds · 2014–2025

▶$22.6MraisedJan 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan ColmanDirector
  • Ethel RubinDirector
  • Terig HughesExecutive Officer
  • Kim NguyenDirector
  • Salvatore Thomas ButeraExecutive Officer
  • Rodney RootsaertExecutive Officer
  • Louise BatchelorExecutive Officer
  • Gael ForterreExecutive Officer
  • Gaetan MichelExecutive Officer
  • Timothy I StillDirector
  • Phillip BarnesDirector
  • Jasmine KwayExecutive Officer
  • Jacob MicallefExecutive Officer
  • Guy Archibald InnesDirector
  • Cameron ReynoldsExecutive Officer, Director
  • Nicholas PlummerExecutive Officer
  • Mickie HenshallDirector
Offering amount
$22.6M
Amount sold
$22.6M
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedMar 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • RODNEY ROOTSAERTExecutive Officer
  • JASMINE KWAYExecutive Officer
  • MARTIN CHARLES FAULKESExecutive Officer, Director
  • JACOB MICALLEFExecutive Officer
  • GAEL FORTERREExecutive Officer
  • TERIG HUGHESExecutive Officer
  • ALAN COLMANDirector
  • MICKIE HENSHALLDirector
  • PHILLIP BARNESDirector
  • EDWARD FUTCHERDirector
  • NICHOLAS PLUMMERExecutive Officer
  • GAETAN MICHELExecutive Officer
  • LOUISE BATCHELORExecutive Officer
  • GUY ARCHIBALD INNESDirector
  • KIM NGUYENDirector
  • CAMERON REYNOLDSExecutive Officer, Director
  • SALVATORE THOMAS BUTERAExecutive Officer
Offering amount
$100K
Amount sold
$100K
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$24MraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rodney RootsaertExecutive Officer
  • Habib SkaffDirector
  • David Cecil VanstonExecutive Officer
  • Guy Archibald InnesDirector
  • Martin Charles FaulkesDirector
  • Jason TerrellExecutive Officer
  • Cameron ReynoldsExecutive Officer, Director
  • Edward FutcherDirector
  • Jacob MicallefExecutive Officer
  • Alan ColmanDirector
Offering amount
$24M
Amount sold
$24M
First sale
Aug 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$721.8KraisedNov 2014 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cameron ReynoldsExecutive Officer, Director
  • Rodney Gerard RootsaertExecutive Officer
  • Alan ColmanDirector
  • Guy Archibold InnesDirector
  • Martin FaulkesDirector
  • Habib SkaffDirector
  • Mike O'ConnellExecutive Officer
Offering amount
$721.8K
Amount sold
$721.8K
Sales commissions
$57K
Placement agents
GVC Capital LLC
First sale
Nov 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$750KraisedOct 2014 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin FaulkesDirector
  • Cameron ReynoldsExecutive Officer, Director
  • Guy Archibold InnesDirector
  • Rodney Gerard RootsaertExecutive Officer
  • Mike O'ConnellExecutive Officer
  • Alan ColmanDirector
  • Habib SkaffDirector
Offering amount
$750K
Amount sold
$750K
Sales commissions
$60K
Placement agents
GVC Capital LLC
First sale
Sep 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$229.4KraisedOct 2014 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mike O'ConnellExecutive Officer
  • Rodney Gerard RootsaertExecutive Officer
  • Guy Archibold InnesDirector
  • Alan ColmanDirector
  • Martin FaulkesDirector
  • Habib SkaffDirector
  • Cameron ReynoldsExecutive Officer, Director
Offering amount
$229.4K
Amount sold
$229.4K
First sale
Oct 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedSep 2014 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Guy Archibold InnesDirector
  • Cameron ReynoldsExecutive Officer, Director
  • Rodney Gerard RootsaertExecutive Officer
  • Mike O'ConnellExecutive Officer
  • Martin FaulkesDirector
  • Habib SkaffDirector
  • Alan ColmanDirector
Offering amount
$1.2M
Amount sold
$1.2M
Sales commissions
$59.9K
Placement agents
"Founding Asset Management (""FAM"")"
First sale
Sep 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedMar 2014 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CAMERON REYNOLDSExecutive Officer, Director
  • MALCOLM LEWINExecutive Officer
  • RODNEY GERARD ROOTSAERTExecutive Officer
  • MARTIN FAULKESDirector
  • GUY ARCHIBALD INNESDirector
  • ALAN COLMANDirector
Offering amount
$3M
Amount sold
$3M
Finders' fees
$160K
Placement agents
Founding Asset Management, Lake Street Capital Markets, MZ Advisory Pte Ltd
First sale
Feb 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
IDEXX Laboratories, Inc.56 shared keywordsIDEXX provides diagnostic products and services for veterinary medicine, including reference laboratory testing, point-of-care analyzers such as the inVue Dx, and practice management software. It also offers continuing education through the IDEXX Learning Center for veterinary professionals.

Companies competing with Volitionrx for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Volitionrx do?
Volition develops Nu.Q epigenetics-based blood tests that detect nucleosome changes associated with cancer, sepsis, and other diseases in both humans and animals. Its products include diagnostic assays for NETosis detection, research-use assays, and a canine cancer blood test.
Who founded Volitionrx?
Volitionrx was founded by Jacob Micallef, Jake Micallef, Mark Eccleston.
How much funding has Volitionrx raised?
Volitionrx has disclosed $52.6M raised across 8 rounds.
Where is Volitionrx headquartered?
Volitionrx is headquartered in Henderson, US.